Eli Lilly and Company · 2025 Q4
ReportedFeb 4, 2026
Period endedDec 31, 2025
Rule of 40+46
Reported this quarter
Revenue
$19.29B
QoQ +9.6%
YoY +42.6%
EPS
$7.39
QoQ +19.0%
YoY +51.4%
Free Cash Flow
$678M
QoQ -90.0%
YoY -30.7%
Gross Margin
82.5%
QoQ -0.4 pp
YoY +0.3 pp
FCF Margin
3.5%
QoQ -34.8 pp
YoY -3.7 pp
P/E Ratio
46.6
QoQ +25.3%
YoY -29.0%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 59478.
HTML
8-K results announcement
Filed Feb 4, 2026
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
194 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2025, filed Feb 12, 2026
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure LLY has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for 2025 Q4, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings
Coverage around this release
R40
HIMS Perfect Storm: FDA, DOJ, and Novo Nordisk Close In — Stock Down 75% From Highs
News · Feb 12, 2026
R40
Hims Launches $99 GLP-1 Pill, Undercuts Novo Nordisk by 90%
News · Feb 5, 2026
News
Eli Lilly Stock Rebounds After FDA Crackdown on Weight-Loss Drug Copies
News
Eli Lilly Outperforms Novo Nordisk Amid Patient Preference Shift
News
Eli Lilly Shares Boosted by GLP-1s
News
Eli Lilly Beats Earnings Expectations on GLP-1 Demand
News
Lilly Reports Fourth-Quarter 2025 Financial Results and Provides 2026 Guidance
News
Lilly Selects Pennsylvania for Newest Injectable Medicine Manufacturing Facility